Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

ESMO Open · Elsevier

Аннотация

Publication date: Available online 9 October 2026 Source: ESMO Open Author(s): T. Macarulla, R. Pazo Cid, M.S. Womack, A. Cubillo Gracian, A. Zervoudakis, H. Hatoum, V. Chung, A. Patel, A.S. Paulson, S. Pant, E.M. O’Reilly, R.A. Hubner, E. Van Cutsem, T. Bekaii-Saab, L. Zhang, J. Li, H. Chen, F. Maxwell, Z.A. Wainberg, D. Melisi

Читать у издателя →

Похожие статьи